# WuXi XDC

ADC-focused CRDMO spun out of WuXi Biologics and WuXi AppTec, covering the whole antibody-drug-conjugate chain from linker-payload synthesis and bioconjugation through GMP fill-finish, with the WuXiDARx conjugation platform and a Singapore dual-sourcing site planned to be operational in 2026.


Source: https://en.bioecon.ru/companies/wuxi-xdc/
Updated: 2026-09-18

- Country: China
- Ticker: HKEX: 2268

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Production site | GMP manufacturing at Wuxi and Changzhou, China, with a Singapore site planned to be operational in 2026 | https://www.wuxixdc.com/en/ |
| Capacity | Payload and linker GMP from gram to >10 kg scale at an OEL of 10 ng/m3 (OEB-5); drug-product filling up to 15 million doses per year in 2R vials | https://www.wuxixdc.com/en/ |
| Capacity | Conjugation production from 5 L to 2,000 L with mAb drug substance integrated in the same building | https://www.wuxixdc.com/en/ |
| Headcount | About 1,000+ employees worldwide | https://www.wuxixdc.com/en/ |
| Funding | Listed on the Hong Kong Stock Exchange, stock code 2268 | https://www.wuxixdc.com/en/ |
| Certification | GMP compliance with FDA, EMA and NMPA regulations | https://www.wuxixdc.com/en/ |
| Revenue | Revenue and profit growing rapidly as the global ADC CRDMO leader [medium confidence] | https://www.leadingir.com/datacenter/view/11886.html |

Independent sources: leadingir.com

## Technologies

- [ADC linker chemistry](https://en.bioecon.ru/technology/adc-linker-chemistry/)